Full-Time

Associate Director

Disclosure Quality & Operations

Posted on 8/19/2026

Deadline 8/24/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$142.4k - $224.1k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

North Wales, PA, USA + 1 more

More locations: Rahway, NJ, USA

Hybrid

Hybrid work arrangement; travel is approximately 10%.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
SharePoint
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Merck

See people who can refer or advise you

Requirements
  • A bachelor's degree or higher, preferably in a health, scientific, or relevant discipline such as life sciences, pharmacy, medicine, or public health, and at least 5 years of relevant industry experience.
  • Fluency in American English.
  • Proficiency in Microsoft Office Suite, including Word, Excel, and PowerPoint, Adobe Acrobat, SharePoint, and electronic document management systems.
  • Strong teamwork and leadership skills across organizational levels, including conflict resolution expertise and discretion.
  • Strong project management, organizational, and multitasking abilities.
  • Demonstrated ability to influence and lead in driving organizational change.
  • Excellent communication, interpersonal, and collaboration skills, with the ability to work independently and in cross-functional teams.
  • An analytical mindset with problem-solving skills and the ability to manage complex, ambiguous situations.
  • A strong commitment to quality, attention to detail, and the ability to meet deadlines under pressure.
  • Adaptability to evolving technologies and processes within Clinical and Regulatory Strategic Communications and regulatory environments.
  • Ability to maintain confidentiality and adhere to regulatory and company standards.
  • Experience writing or the ability to critically analyze and interpret drug and/or device clinical submission documents.
  • Ability to execute responsibilities with minimal oversight.
  • Ability to think strategically and objectively, with creativity and innovation.
  • Critical thinking, cross-cultural awareness, Good Clinical Practice, independent thinking, medical writing, new technology integration, people leadership, process improvements, regulatory compliance, and stakeholder management.
Responsibilities
  • Supervise the creation, review, quality control, and/or redaction of clinical documents across multiple therapeutic areas and development stages, verifying accuracy, consistency, and proper formatting in accordance with company and regulatory guidance and privacy and transparency regulations.
  • Oversee project timelines and tracking to drive timely completion of deliverables, ensure compliance with global requirements and voluntary policies, and maintain inspection readiness.
  • Lead the collection and analysis of metrics to identify trends, diagnose root causes, and drive corrective actions through targeted process improvements, enhanced training programs, and other strategic measures.
  • Build and maintain cooperative relationships with internal stakeholders relevant to the role, policies, and regulations.
  • Forecast and allocate resources for deliverables while tracking milestones, documents, and submission-management systems to identify trials and submissions within the scope of transparency regulations.
  • Coordinate and/or support collaborative reviews with authors and product development team members to confirm that information and documentation are reviewed and approved for accuracy and, when applicable, confidential and privacy protection.
  • Lead and support clinical trial disclosures, document redactions, and other departmental initiatives to maintain compliance with regulatory requirements, organizational standards, and public registries.
  • Collaborate in the development, maintenance, and continuous updating of standard operating procedures, job aids, and guidance documents for clarity, compliance, and alignment with evolving regulatory and organizational requirements.
  • Support regulatory audits and inspections by ensuring documentation readiness, facilitating responses, and coordinating with cross-functional teams to maintain compliance standards.
  • Strategize, design, and implement efficient processes, technology, and tools to enhance business operations, document organization, authoring workflows, and metrics collection.
  • Lead the development and execution of training programs, including cross-training initiatives for medical writers and other cross-functional teams, standardized learning materials, and continuous-improvement activities.
  • Mentor and manage team members, including hiring, workload management, professional development, and performance management.
  • Drive administration and business objectives for the group.
Desired Qualifications
  • Expert-level proficiency in United States Food and Drug Administration trial disclosure or European Medicines Agency and/or Health Canada publication of clinical information requirements.
  • Expert knowledge of regulatory disclosure intelligence and industry trends, with the ability to assess impacts on business operations and shape strategies for new or modified requirements.
  • Ability to track metrics, analyze data, and establish automation tools.
  • Proven experience developing, testing, implementing, and supporting tools and systems.
  • Demonstrated experience identifying, designing, and implementing process improvements that increase efficiency, reduce cycle times, and strengthen operational effectiveness.
  • Experience applying quality principles, root cause analysis, and corrective actions to support compliant, inspection-ready deliverables.
  • Ability to influence stakeholders across functions to align priorities, drive adoption of process improvements, and support sustained quality outcomes.
  • Continuous improvement.
  • Standard operating procedure expertise.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.

INACTIVE